FDA Rounded out 2019 by Approving a New Treatment for Pancreatic Cancer

In the final days of 2019, the U.S. Food and Drug Administration (FDA) approved expanding the use of a previously approved molecularly targeted therapeutic called olaparib (Lynparza) to include treating certain patients diagnosed with one of the deadliest types of cancer—pancreatic cancer.

Read More

Second Targeted Therapeutic Approved for Use Based on Tumor Biomarker, Not Tumor Origin

Last week, the U.S. Food and Drug Administration (FDA) approved the second of a new wave of molecularly targeted therapeutics that can be used to treat patients with any type of cancer provided their tumor tests positive for a specific biomarker.

The therapeutic in question, entrectinib (Rozlytrek), was approved for treating adults and adolescents age 12 and older whose cancers have an NTRK gene fusion and who have no other effective treatment options.

Read More